Neutrophil-induced human bronchial hyperresponsiveness in vitro--pharmacological modulation

Clin Exp Allergy. 1993 Apr;23(4):251-6. doi: 10.1111/j.1365-2222.1993.tb00318.x.

Abstract

Although it has been postulated that inflammatory cells cause the bronchial hyperresponsiveness which is diagnostic of asthma, until recently there has been little direct evidence of such a link. We have recently shown that calcium ionophore-activated human neutrophils and eosinophils can induce a state of human airway hyperresponsiveness in vitro. In this study we have shown that the anti-inflammatory agent nedocromil sodium, 10(-7) M, inhibited the hyperresponsiveness induced by products released from ionophore activated neutrophils but did not inhibit the release of leukotriene B4 from the same cells. Neutrophil-induced bronchial hyperresponsiveness was also inhibited by pre-treatment of the bronchial tissues with a thromboxane A2 and prostaglandin receptor antagonist, GR32191, 10(-7) M. These findings indicate that cyclooxygenase products are involved in bronchial hyperresponsiveness induced by inflammatory cell products in vitro and that their release can be inhibited by nedocromil sodium.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biphenyl Compounds / pharmacology
  • Bronchi / drug effects*
  • Bronchial Hyperreactivity / pathology*
  • Calcimycin / pharmacology
  • Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology
  • Heptanoic Acids / pharmacology
  • Histamine / pharmacology
  • Humans
  • Leukotriene B4 / metabolism
  • N-Formylmethionine Leucyl-Phenylalanine / pharmacology
  • Nedocromil
  • Neutrophils / drug effects*
  • Neutrophils / physiology
  • Quinolones / pharmacology
  • Receptors, Thromboxane / antagonists & inhibitors

Substances

  • Biphenyl Compounds
  • Heptanoic Acids
  • Quinolones
  • Receptors, Thromboxane
  • Nedocromil
  • Leukotriene B4
  • Calcimycin
  • N-Formylmethionine Leucyl-Phenylalanine
  • Histamine
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • vapiprost